As leaders in liver disease and transplantation, Einstein specialists research liver diseases (including primary biliary cirrhosis)
and treatments such as the use of anti-rejection and anti-infection treatments after transplantation.
Ongoing studies our liver experts are involved in include early medical treatment with innovative and investigational drugs
for patients whose livers, native or transplanted, have failed. Studies Einstein is involved in include:
Photodynamic Therapy System for Patients with Refractory/Unresponsive Solid Tumors -- In this study, patients with liver metastases or solid tumors elsewhere in the body that have failed to respond to conventional
chemotherapy and radiation will receive an investigational drug (LS11) activated by a flexible catheter with a light. This
therapy may result in the destruction of tumor tissue.
Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon Plus Ribavirin -- The current treatment for Hepatitis C infection in previously untreated patients is successful in only about half of patients.
There is no therapy for non-responders. This study examines the effectiveness of the drug thymosin with interferon in patients
with cirrhosis who have not responded to conventional therapy.
Thymosin Plus PEG-Interferon in Non-Chronic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin -- The current treatment for Hepatitis C infection in previously untreated patients is successful in only about half of patients.
There is no therapy for non-responders. This study examines the effectiveness of the drug thymosin with interferon in patients
without cirrhosis who have not responded to conventional therapy.
The Use of Pegylated Interferon and Ribaviron After Liver Transplantation -- In this clinical research study, hepatologists are testing the success and efficacy of this powerful Hepatitis B treatment
following liver transplantation. Preliminary results demonstrate that patients involved in this study have an excellent response
to this treatment regimen.
Hepatoma and Liver Transplant Multicenter Database (HALT) -- In cooperation with other regional centers in New Jersey and New York, the goal of this project is to improve outcomes
and optimize therapy for patients suffering from liver cancer.
Novel Immunosuppressive Strategies for Liver Recipients Receiving Maintenance Therapy - Sirolimus Conversion Study -- This trial offers options for those patients who have side effects from current maintenance regimens, based on tacrolimus
or cyclosporine, to switch to a less toxic baseline immunosuppressive regimen.
Bone Marrow Aspiration Protocol to Detect Occult Micrometastases From Hepatomas -- This protocol will optimize patient selection and outcomes for patients with hepatomas and cirrhosis.
Acute Liver Failure -- Einstein hepatologists participated in a nationwide study to determine whether treatment with N-Acetyl-Cysteine (NAC)
may avoid liver failure in some patients. (Study concluded).
